Last reviewed · How we verify
Cayston®
Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs.
Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs. Used for Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
At a glance
| Generic name | Cayston® |
|---|---|
| Sponsor | Mylan Inc. |
| Drug class | Monobactam antibiotic |
| Target | Bacterial penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Aztreonam lysine is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. When inhaled as a powder, it achieves high local concentrations in the airways, effectively penetrating and disrupting biofilms formed by Pseudomonas aeruginosa in cystic fibrosis patients, thereby reducing bacterial burden and improving lung function.
Approved indications
- Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
Common side effects
- Cough
- Wheezing
- Dyspnea
- Bronchospasm
- Hemoptysis
Key clinical trials
- Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (PHASE3)
- Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis (PHASE4)
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) (PHASE3)
- Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (PHASE3)
- Aztreonam Lysine for Pseudomonas Infection Eradication Study (PHASE2)
- Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |